Dr. John Cush

Know-it-Now. Info on RA, Stills disease, Lupus, Gout, Pregnancy, Spondylitis, Psoriasis, Drug Safety, Rheumatology Research, Medical Education & Drug Evaluation

[Dr. John Cush @RheumNow]

EULAR26: Reports on Systemic Sclerosis

https://t.co/knZZlMYlen

[Dr. John Cush @RheumNow]

Brenda McShan: The Creative Heart of RheumNow

A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.

https://t.co/b4fmN1bpFG

[Dr. John Cush @RheumNow]

Generic Tofacitinib (6.26.2026)

Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI.

https://t.co/DNWh7taaN6

[Dr. John Cush @RheumNow]

EULAR26: Updates in SLE and APS

Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.

https://t.co/DP7gPvlGhU

[Dr. John Cush @RheumNow]

My take on diet based intervention studies presented at #EULAR2026
It's all in the title: Diet as a DMARD? The Evidence Is Still Hard to Swallow

https://t.co/JDVlaOsC6w

Head to @RheumNow.com to have a read and for more faculty articles! https://t.co/luV3zZTKOU

[Dr. John Cush @RheumNow]

An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment?
🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/KfkpMpciEf

[Rheuma Doc @LastManStand85]

Is it all over for avacopan? #Vasculitis

https://t.co/1sFUidC6Cw

[Dr. John Cush @RheumNow]

RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255

[Dr. John Cush @RheumNow]

RT @drminidey

#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile. https://t.co/0jEGHrvLv2

[Dr. John Cush @RheumNow]

Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D.

[Dr. John Cush @RheumNow]

Obexelimab in IgG4-Related Disease: INDIGO Trial

Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.

https://t.co/Wid9ZzESae

[Dr. John Cush @RheumNow]

2026 Guidelines for the Treatment of Axial Spondyloarthritis

New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap.

https://t.co/mf0LjkPeGx

[Dr. John Cush @RheumNow]

Self-Directed Cognitive Behavioral Therapy for Chronic Pain

Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?

https://t.co/P2DDvCiLNL

[Dr. John Cush @RheumNow]

EULAR26: Pitfalls in T2T

EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated.

https://t.co/KV9ExsvccS

[Dr. John Cush @RheumNow]

2-Gene Blood Test for Kawasaki Disease in Febrile Children

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.

https://t.co/Pwb23fOcO9

[Dr. John Cush @RheumNow]

True or False: A 5-year retrospective study found that platelet-rich plasma injections significantly outperformed NSAIDs when given to early knee osteoarthritis patients. See if you got it right in this week's RheumIQ quiz at https://t.co/Z8XFynKJ0o.

[Dr. John Cush @RheumNow]

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA

See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact.

https://t.co/KfkpMpciEf

[Dr. John Cush @RheumNow]

JAMA Review on Low Back Pain

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE.

https://t.co/wQ1GA8IqIO

[Dr. John Cush @RheumNow]

Missed a session at EULAR 2026?

No problem.

The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, we've got your EULAR recap covered.

Start exploring the coverage today on https://t.co/0Y88mz32NI

[Dr. John Cush @RheumNow]

Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological state. https://t.co/tCfyCaGbiD